Melissa X Shi

6PUBLICATIONS
42CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursCell development, proliferation and death
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Apr 06, 2024
A novel inhibitory BAK antibody enables assessment of non-activated BAK in cancer cells.

Hema Preethi Subas Satish, Sweta Iyer, Melissa X Shi

|Mar 25, 2022
BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells.

Diane Moujalled, Adam G Southon, Eiman Saleh

|Mar 13, 2022
Structure of the BAK-activating antibody 7D10 bound to BAK reveals an unexpected role for the α1-α2 loop in BAK activation.

Adeline Y Robin, Michelle S Miller, Sweta Iyer

|Apr 07, 2021
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias.

Rachel Thijssen, Sarah T Diepstraten, Donia Moujalled

|Apr 25, 2020
Robust autoactivation for apoptosis by BAK but not BAX highlights BAK as an important therapeutic target.

Sweta Iyer, Rachel T Uren, Michael A Dengler

|Feb 10, 2017
Disordered clusters of Bak dimers rupture mitochondria during apoptosis.

Rachel T Uren, Martin O'Hely, Sweta Iyer

Pageof 1